Clinical Trial Update: A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating a combination of NeoRecormon (epoetin beta), CellCept (mycophenolate mofetil), and prednisone in patients with low- or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)
• NeoRecormon (epoetin beta)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED | Results posted: 2016-06-23